Newer Migraine Drugs Linked to a 40% Higher Risk of Miscarriage in Pregnant Women, Study Suggests — Study Raises Questions About the Pregnancy Safety of CGRP-Targeting Treatments, but Further Research Is Needed to Determine Whether the Medications Directly Contribute to Pregnancy Loss.

CGRP-targeting migraine drugs were associated with a higher miscarriage rate in the AM-PREGNANT cohort released at AHS 2026: roughly 5% in users versus about 2% in non-users, a relative increase of about 45%. The observational cohort covered 7,119 women and 7,579 pregnancies and cannot establish that the drugs cause pregnancy loss. Clinicians prescribing CGRP agents to women of childbearing potential will need to weigh this signal against the drugs' benefits.